Moneycontrol Bureau
Cadila Healthcare slightly missed street expectations on bottomline and topline front but the operating performance was ahead of estimates. Net profit during October-December quarter climbed 51.6 percent year-on-year to Rs 282 crore on consolidated basis, driven by strong operating performance and growth in US business.
A CNBC-TV18 poll had estimated profit at Rs 288.5 crore on revenue of Rs 2,205 crore for the quarter.
Consoldiated revenue of the pharmaceutical firm grew 17 percent to Rs 2,189.5 crore during October-December quarter from Rs 1,872 crore in same quarter last fiscal.
Operating profit (EBITDA) surged 51.5 percent year-on-year to Rs 447 crore and margin expanded 460 basis points to 20.4 percent in the quarter gone by (against expectations of 40.8 percent and 304 basis points growth, respectively).
US business growth was 42 percent during the quarter against estimates of around a 35 percent growth. Revenue from emerging markets increased 23 percent.
Cadila filed 5 additional ANDAs in Q3, taking total ANDAs to 255 at the end of December 2014.
At 13:51 hours IST, the scrip of Cadila Healthcare was quoting at Rs 1,516.95, up Rs 41.35, or 2.80 percent on the BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
